Alumis Inc. (ALMS) – What Are Researchers Thinking About This Stock?

Alumis Inc. (NASDAQ:ALMS) has received a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $33.27.

A number of analysts have commented on ALMS shares. Morgan Stanley reduced their price objective on shares of Alumis from $39.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, September 2nd. Oppenheimer decreased their target price on Alumis from $55.00 to $37.00 and set an “outperform” rating for the company in a research report on Wednesday, September 2nd. Benchmark reiterated a “buy” rating on shares of Alumis in a report on Monday, October 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Wednesday, September 16th. Finally, Wells Fargo & Company reduced their price target on shares of Alumis from $51.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, September 2nd.

Insider Activity

In other news, insider Mark Bradley sold 2,572 shares of Alumis stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $67,823.64. Following the completion of the sale, the insider directly owned 48,533 shares in the company, valued at $1,279,815.21. The trade was a 5.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Srinivas Akkaraju sold 96,131 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $10.55, for a total value of $1,014,182.05. Following the completion of the sale, the director directly owned 2,025,493 shares of the company’s stock, valued at approximately $21,368,951.15. The trade was a 4.53% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 111,084 shares of company stock valued at $1,408,493. 33.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALMS. Integrated Wealth Concepts LLC acquired a new position in shares of Alumis during the 2nd quarter valued at about $33,000. Strs Ohio raised its stake in shares of Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after acquiring an additional 1,500 shares in the last quarter. KBC Group NV acquired a new stake in Alumis in the 1st quarter worth approximately $42,000. State of Wyoming acquired a new stake in Alumis in the 1st quarter worth approximately $57,000. Finally, Dimensional Fund Advisors LP boosted its position in Alumis by 12.7% during the first quarter. Dimensional Fund Advisors LP now owns 23,115 shares of the company’s stock worth $509,000 after purchasing an additional 2,599 shares during the period.

Alumis Price Performance

ALMS stock opened at $6.12 on Monday. The firm has a market cap of $792.11 million, a PE ratio of -1.59 and a beta of -0.38. Alumis has a 12 month low of $4.37 and a 12 month high of $31.35. The firm has a 50 day simple moving average of $13.24 and a 200 day simple moving average of $20.61.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.34). The company had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million. Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. As a group, sell-side analysts expect that Alumis will post -2.95 earnings per share for the current year.

About Alumis

Alumis, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s research centers on selective allosteric inhibitors of tyrosine kinase 2 (TYK2), a protein involved in signaling pathways that regulate inflammation and immune responses.

Alumis’ lead product candidate is ESK-001, an oral, highly selective TYK2 inhibitor being evaluated in inflammatory and autoimmune conditions, including plaque psoriasis, psoriatic arthritis and systemic lupus erythematosus.